UM  > 健康科學學院
Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: A systematic review and meta-analysis
He L.4; Liu S.1; Shan C.2; Tu Y.1; Li Z.1; Zhang X.D.3
2016-09-07
Source PublicationBMC Pharmacology and Toxicology
ISSN20506511
Volume17Issue:1
AbstractBackground: It has been observed that the efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors as compared to the placebo groups in some clinical trials conducted in China is weaker than that in trials conducted outside China, leading to the suspicion that this may be caused by differential Glycosylated Hemoglobin (HbA1c) response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries. Methods: We searched published articles and other documents related to phase III placebo-control trials of DPP-4 inhibitors in Type 2 diabetes mellitus (T2DM). We included studies from different countries and compared those conducted in China to those conducted in other countries. Meta-regression analysis was used to analyze the HbA1c response in the placebo arms. Results: A total of 66 studies met the inclusion criteria and 10 were conducted within China. There were a total of 8303 participants (mean age 56, male 57 %) in placebo groups. The pooled change in HbA1c for the placebo groups of 10 trials conducted in patients with T2DM in China was 0.26 % (95 % CI [-0.36 %, -0.16 %], p-value < 0.001), compared to 0.015 % (95 % CI [-0.05 %, 0.08 %], p-value is 0.637) for 56 trials conducted outside of China. The difference of placebo effect between trials conducted in and outside China is -0.273 % (95 % CI [-0.42 %, -0.13 %], p-value is less than 0.001) while after excluding trials conducted in Japan, the difference is -0.203 % (95 % CI [-0.35 %, -0.06 %], p-value is 0.005). They are both statistically significant. Conclusions: The meta-analysis in the article demonstrates that there is statistically significant difference in the HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries. This differential HbA1c response in the placebo arm should be taken into consideration by both experimenters and medical decision makers when future DPP-4 studies are conducted in China.
KeywordDiabetes mellitus Differential HbA1c response Dipeptidyl peptidase-4 inhibitor Meta-analysis T2DM
DOI10.1186/s40360-016-0084-7
URLView the original
Language英語
Fulltext Access
Citation statistics
Cited Times [WOS]:2   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionFaculty of Health Sciences
Affiliation1.MSD R and D (China) Co., Ltd.
2.National Institutes for Food and Drug Control
3.Universidade de Macau
4.Australian National University
Recommended Citation
GB/T 7714
He L.,Liu S.,Shan C.,et al. Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: A systematic review and meta-analysis[J]. BMC Pharmacology and Toxicology,2016,17(1).
APA He L.,Liu S.,Shan C.,Tu Y.,Li Z.,&Zhang X.D..(2016).Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: A systematic review and meta-analysis.BMC Pharmacology and Toxicology,17(1).
MLA He L.,et al."Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: A systematic review and meta-analysis".BMC Pharmacology and Toxicology 17.1(2016).
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[He L.]'s Articles
[Liu S.]'s Articles
[Shan C.]'s Articles
Baidu academic
Similar articles in Baidu academic
[He L.]'s Articles
[Liu S.]'s Articles
[Shan C.]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[He L.]'s Articles
[Liu S.]'s Articles
[Shan C.]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.